Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4 T Cells From HIV-1 Patients

Overview

Journal Front Virol

Specialty Microbiology

Date 2022 Aug 15

PMID 35967461

Authors

Cristina Xufre

Tania Gonzalez

Lorna Leal

Charles M Trubey

Jeffrey D Lifson

Jose Maria Gatell

Jose Alcami

Nuria Climent

Felipe Garcia

Sonsoles Sanchez-Palomino

Affiliations

Soon will be listed here.

Abstract

We described a novel HIV autologous isolation method based in coculturing macrophages and CD4T-cell-enriched fractions from peripheral blood collected from antiretroviral-treated (ART) HIV patients. This method allows the isolation of high viral titers of autologous viruses, over 10HIV RNA copies/ml, and reduces the time required to produce necessary amounts for virus for use as antigens presented by monocyte-derived myeloid cells in HIV therapeutic vaccine approaches. By applying these high titer and autologous virus produced in the patient-derived cells, we intended to elicit a boost of the immunological system response in HIV therapeutic vaccines in clinical trials.

References

Whiteside T, Piazza P, Reiter A, Stanson J, Connolly N, Rinaldo Jr C . Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol. 2008; 16(2):233-40. PMC: 2643533. DOI: 10.1128/CVI.00066-08. View

Garcia F, Climent N, Guardo A, Gil C, Leon A, Autran B . A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013; 5(166):166ra2. DOI: 10.1126/scitranslmed.3004682. View

Rodari A, Darcis G, Van Lint C . The Current Status of Latency Reversing Agents for HIV-1 Remission. Annu Rev Virol. 2021; 8(1):491-514. DOI: 10.1146/annurev-virology-091919-103029. View

Wang X, Xu H . Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption. Viruses. 2021; 13(2). PMC: 7926539. DOI: 10.3390/v13020335. View

Sarzotti-Kelsoe M, Bailer R, Turk E, Lin C, Bilska M, Greene K . Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2013; 409:131-46. PMC: 4040342. DOI: 10.1016/j.jim.2013.11.022. View

Churchill M, Deeks S, Margolis D, Siliciano R, Swanstrom R . HIV reservoirs: what, where and how to target them. Nat Rev Microbiol. 2015; 14(1):55-60. DOI: 10.1038/nrmicro.2015.5. View

Stebbing J, Gazzard B, Douek D . Where does HIV live?. N Engl J Med. 2004; 350(18):1872-80. DOI: 10.1056/NEJMra032395. View

Lu W, Arraes L, Ferreira W, Andrieu J . Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004; 10(12):1359-65. DOI: 10.1038/nm1147. View

Palucka K, Banchereau J . Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39(1):38-48. PMC: 3788678. DOI: 10.1016/j.immuni.2013.07.004. View

10.

Leal L, Couto E, Sanchez-Palomino S, Climent N, Fernandez I, Miralles L . Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial. Front Immunol. 2021; 12:767370. PMC: 8632026. DOI: 10.3389/fimmu.2021.767370. View

11.

Ong S, Hadadi E, Dang T, Yeap W, Tan C, Ng T . The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence. Cell Death Dis. 2018; 9(3):266. PMC: 5833376. DOI: 10.1038/s41419-018-0327-1. View

12.

Leal L, Lucero C, Gatell J, Gallart T, Plana M, Garcia F . New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017; 16(6):587-600. DOI: 10.1080/14760584.2017.1322513. View

13.

Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V . Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis. 2005; 191(10):1680-5. DOI: 10.1086/429340. View

14.

Campbell J, Hearps A, Martin G, Williams K, Crowe S . The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS. 2014; 28(15):2175-87. PMC: 6331181. DOI: 10.1097/QAD.0000000000000408. View

15.

Vandergeeten C, Fromentin R, Merlini E, Lawani M, DaFonseca S, Bakeman W . Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol. 2014; 88(21):12385-96. PMC: 4248919. DOI: 10.1128/JVI.00609-14. View

16.

Garcia F, Climent N, Assoumou L, Gil C, Gonzalez N, Alcami J . A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis. 2011; 203(4):473-8. PMC: 3071229. DOI: 10.1093/infdis/jiq077. View

17.

Kapellos T, Bonaguro L, Gemund I, Reusch N, Saglam A, Hinkley E . Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases. Front Immunol. 2019; 10:2035. PMC: 6728754. DOI: 10.3389/fimmu.2019.02035. View

18.

Walsh S, Bhardwaj N, Gandhil R . Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. Curr HIV Res. 2004; 1(2):205-16. DOI: 10.2174/1570162033485285. View

19.

Garcia F, Plana M, Vidal C, Cruceta A, OBRIEN W, Pantaleo G . Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999; 13(11):F79-86. DOI: 10.1097/00002030-199907300-00002. View

20.

El-Sadr W, Lundgren J, Neaton J, Gordin F, Abrams D, Arduino R . CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355(22):2283-96. DOI: 10.1056/NEJMoa062360. View